8.650GBp0.00%Mkt Cap: 18.86M GBpP/E: —Last update: 2026-06-01
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collectio…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap18.86M GBp
Enterprise Value6.90M GBp
Revenue (TTM)7.28M GBp
Gross Profit3.18M GBp
Net Income (TTM)-1.65M GBp
Revenue/Share0.0780 GBp
Last Price8.650 GBp
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees79
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.83
PEG—
EV/EBITDA-2.59
EV/Revenue0.95
P/S2.59
P/B0.68
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
6.26027% of range15.00
52W High15.00 GBp
52W Low6.260 GBp
Profitability
Gross Margin48.71%
Oper. Margin-31.43%
EBITDA Margin-36.67%
Profit Margin-25.27%
ROE-14.07%
ROA-11.93%
Growth
Revenue Growth23.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.01M GBp
CapEx (TTM)870.00K GBp
FCF Margin-43.73%
FCF Yield-16.87%
Net Debt-1.12M GBp
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.02
Current Ratio2.83
Quick Ratio2.83
Book Value/Sh0.1270 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateSep 4, 2013
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)26.00 GBp
Target Range26.00 GBp – 26.00 GBp
# Analysts1
Ownership
Shares Out.218.05M
Float41.02M
Insiders4.89%
Institutions82.94%
Technical
SMA 507.484 (+15.6%)
SMA 20010.08 (-14.2%)
Beta0.07
S&P 52W Chg27.94%
Avg Vol (30d)165.63K
Avg Vol (10d)267.74K
Technical Indicators
RSI (14)77.1
MACD0.4067
MACD Signal0.2171
MACD Hist.+0.1895
BB Upper9.420 GBp
BB Middle7.530 GBp
BB Lower5.640 GBp
BB Width50.19%
ATR (14)0.5903 GBp
Vol Ratio (20d)0.73x